Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hepatitis C, Chronic|Hepatitis A|Hepatitis C|HIV Infections|Liver Cirrhosis|Acquired Immunodeficiency Syndrome
Phase 2: Hepatitis C, Chronic|Hepatitis C|Hepatitis A
Phase 1: Healthy Volunteers|Hepatitis C|Hepatitis A|Hepatitis C, Chronic|Kidney Diseases|Liver Cirrhosis|HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TRK-450-0203 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2017-09-01 |
|
TRK-450-0201 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2016-12-01 |
|
2012-003534-17 | P2 |
Completed |
Hepatitis C, Chronic |
2016-06-08 |
|
NCT01608737 | P3 |
Withdrawn |
Hepatitis C, Chronic|Hepatitis A |
2015-10-01 |